Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) Price Target at $7.42

Bausch Health Companies Inc. (NYSE:BHC) has earned a consensus rating of “Reduce” from the seven brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $7.42.

A number of equities analysts recently issued reports on the stock. Wall Street Zen lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. Royal Bank of Canada raised their price target on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a “sector perform” rating in a research report on Friday, May 2nd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th.

Institutional Investors Weigh In On Bausch Health Companies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Merit Financial Group LLC bought a new position in shares of Bausch Health Companies during the 4th quarter worth about $228,000. SG Americas Securities LLC lifted its stake in Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after purchasing an additional 1,263,706 shares during the period. DGS Capital Management LLC bought a new position in Bausch Health Companies during the fourth quarter worth about $143,000. Tobam boosted its holdings in Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Principal Securities Inc. grew its stake in shares of Bausch Health Companies by 39.7% in the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock valued at $155,000 after purchasing an additional 5,464 shares during the period. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Up 3.0%

Shares of NYSE BHC opened at $4.59 on Wednesday. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $9.85. The company has a market cap of $1.66 billion, a P/E ratio of -38.21, a P/E/G ratio of 0.37 and a beta of 0.34. The business’s 50 day moving average is $5.20 and its two-hundred day moving average is $6.74.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.